Matinas BioPharma
MTNB
47 hedge funds and large institutions have $15.1M invested in Matinas BioPharma in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 4 closing their positions.
275% more capital inflows, than outflows
Capital inflows: $1.82M | Capital outflows: $484K
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
7% more funds holding
Funds holding: 44 → 47 (+3)
0.69% more ownership
Funds ownership: 11.63% → 12.32% (+0.69%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alliance Wealth Management Group
Flemington,
New Jersey
|
+$536K |
| 2 |
State Street
Boston,
Massachusetts
|
+$301K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$251K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$90.1K |
| 5 |
Morgan Stanley
New York
|
+$78.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$161K |
| 2 |
Millennium Management
New York
|
-$86K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
-$82.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$61K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$44.1K |
MTNB Hedge Fund Activity: Q3 2017 in Review
47 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2017, worth a combined $15.1M — down 16% from $18M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MTNB positions and 4 closed out — a net gain of 4 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Alliance Wealth Management Group, adding an estimated $536K. The largest seller was Royal Bank of Canada, cutting an estimated $161K.
- 47 institutional investors held Matinas BioPharma (MTNB) as of Q3 2017, up from 44 in Q2 2017.
- Funds reported $15.1M of Matinas BioPharma stock for Q3 2017, down 16% quarter-over-quarter.
- 8 funds opened new Matinas BioPharma positions in Q3 2017 and 4 closed out, a net change of +4 holders.
- The largest Matinas BioPharma buyer in Q3 2017 was Alliance Wealth Management Group, an estimated $536K added.
- The largest Matinas BioPharma seller in Q3 2017 was Royal Bank of Canada, an estimated $161K sold.
Based on aggregated 13F filings for Q3 2017.